FBW7 upregulation enhances cisplatin cytotoxicity in non- small cell lung cancer cells.
Asian Pac J Cancer Prev
; 14(11): 6321-6, 2013.
Article
en En
| MEDLINE
| ID: mdl-24377525
INTRODUCTION: Lung cancer is extremely harmful to human health and has one of the highest worldwide incidences of all malignant tumors. Approximately 80% of lung cancers are classified as non-small cell lung cancers (NSCLCs). Cisplatin-based multidrug chemotherapy regimen is standard for such lesions, but drug resistance is an increasing problem. F-box/WD repeat-containing protein 7 (FBW7) is a member of the F-box protein family that regulates cell cycle progression, and cell growth and differentiation. FBW7 also functions as a tumor suppressor. METHODS: We used cell viability assays, Western blotting, and immunofluorescence combined with siRNA interference or plasmid transfection to investigate the underlying mechanism of cisplatin resistance in NSCLC cells. RESULTS: We found that FBW7 upregulation significantly increased cisplatin chemosensitivity and that cells expressing low levels of FBW7, such as NCI-H1299 cells, have a mesenchymal phenotype. Furthermore, siRNA-mediated silencing or plasmid-mediated upregulation of FBW7 resulted in altered epithelial-mesenchymal transition (EMT) patterns in NSCLC cells. These data support a role for FBW7 in regulating the EMT in NSCLC cells. CONCLUSION: FBW7 is a potential drug target for combating drug resistance and regulating the EMT in NSCLC cells.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Cisplatino
/
Carcinoma de Pulmón de Células no Pequeñas
/
Proteínas de Ciclo Celular
/
Ubiquitina-Proteína Ligasas
/
Proteínas F-Box
/
Neoplasias Pulmonares
Límite:
Humans
Idioma:
En
Revista:
Asian Pac J Cancer Prev
Asunto de la revista:
NEOPLASIAS
Año:
2013
Tipo del documento:
Article
Pais de publicación:
Tailandia